187 related articles for article (PubMed ID: 12088927)
21. Expression of cAMP-responsive element binding protein and inducible cAMP early repressor in hyperfunctioning thyroid adenomas.
Peri A; Luciani P; Tonacchera M; Agretti P; Baglioni-Peri S; Buci L; Conforti B; Cioppi F; Biliotti G; Serio M; Vitti P; Chiovato L
Eur J Endocrinol; 2002 Jun; 146(6):759-66. PubMed ID: 12039695
[TBL] [Abstract][Full Text] [Related]
22. Rarity of oncogenic mutations in the thyrotropin receptor of autonomously functioning thyroid nodules in Japan.
Takeshita A; Nagayama Y; Yokoyama N; Ishikawa N; Ito K; Yamashita T; Obara T; Murakami Y; Kuma K; Takamatsu J
J Clin Endocrinol Metab; 1995 Sep; 80(9):2607-11. PubMed ID: 7673402
[TBL] [Abstract][Full Text] [Related]
23. Activating thyrotropin receptor mutations are present in nonadenomatous hyperfunctioning nodules of toxic or autonomous multinodular goiter.
Tonacchera M; Agretti P; Chiovato L; Rosellini V; Ceccarini G; Perri A; Viacava P; Naccarato AG; Miccoli P; Pinchera A; Vitti P
J Clin Endocrinol Metab; 2000 Jun; 85(6):2270-4. PubMed ID: 10852462
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of TSH receptor and Gsalpha mutations in 45 autonomously functioning thyroid nodules in Japan.
Nishihara E; Amino N; Maekawa K; Yoshida H; Ito M; Kubota S; Fukata S; Miyauchi A
Endocr J; 2009; 56(6):791-8. PubMed ID: 19550078
[TBL] [Abstract][Full Text] [Related]
25. Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism.
Paschke R
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():129-32. PubMed ID: 8981020
[TBL] [Abstract][Full Text] [Related]
26. The first activating TSH receptor mutation in transmembrane domain 1 identified in a family with nonautoimmune hyperthyroidism.
Biebermann H; Schöneberg T; Hess C; Germak J; Gudermann T; Grüters A
J Clin Endocrinol Metab; 2001 Sep; 86(9):4429-33. PubMed ID: 11549687
[TBL] [Abstract][Full Text] [Related]
27. High prevalence of TSHR/Gsα mutation-negative clonal hot thyroid nodules (HNs) in a Turkish cohort.
Sancak S; Jaeschke H; Eren F; Tarcin O; Guellueoglu B; Sen LS; Sever Z; Gozu HI; Bircan R; Akalin S; Paschke R; Eszlinger M
Horm Metab Res; 2011 Jul; 43(8):562-8. PubMed ID: 21773967
[TBL] [Abstract][Full Text] [Related]
28. Activating thyrotropin receptor mutations in histologically heterogeneous hyperfunctioning nodules of multinodular goiter.
Tonacchera M; Vitti P; Agretti P; Giulianetti B; Mazzi B; Cavaliere R; Ceccarini G; Fiore E; Viacava P; Naccarato A; Pinchera A; Chiovato L
Thyroid; 1998 Jul; 8(7):559-64. PubMed ID: 9709907
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of mutations in TSHR, GNAS, PRKAR1A and RAS genes in a large series of toxic thyroid adenomas from Galicia, an iodine-deficient area in NW Spain.
Palos-Paz F; Perez-Guerra O; Cameselle-Teijeiro J; Rueda-Chimeno C; Barreiro-Morandeira F; Lado-Abeal J; ; Araujo Vilar D; Argueso R; Barca O; Botana M; Cabezas-Agrícola JM; Catalina P; Dominguez Gerpe L; Fernandez T; Mato A; Nuño A; Penin M; Victoria B
Eur J Endocrinol; 2008 Nov; 159(5):623-31. PubMed ID: 18694911
[TBL] [Abstract][Full Text] [Related]
30. Thyrotropin Causes Dose-dependent Biphasic Regulation of cAMP Production Mediated by G
Neumann S; Malik SS; Marcus-Samuels B; Eliseeva E; Jang D; Klubo-Gwiezdzinska J; Krieger CC; Gershengorn MC
Mol Pharmacol; 2020 Jan; 97(1):2-8. PubMed ID: 31704717
[TBL] [Abstract][Full Text] [Related]
31. Functional characteristics of three new germline mutations of the thyrotropin receptor gene causing autosomal dominant toxic thyroid hyperplasia.
Tonacchera M; Van Sande J; Cetani F; Swillens S; Schvartz C; Winiszewski P; Portmann L; Dumont JE; Vassart G; Parma J
J Clin Endocrinol Metab; 1996 Feb; 81(2):547-54. PubMed ID: 8636266
[TBL] [Abstract][Full Text] [Related]
32. Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ cascades.
Parma J; Van Sande J; Swillens S; Tonacchera M; Dumont J; Vassart G
Mol Endocrinol; 1995 Jun; 9(6):725-33. PubMed ID: 8592518
[TBL] [Abstract][Full Text] [Related]
33. Functioning and nonfunctioning thyroid adenomas involve different molecular pathogenetic mechanisms.
Tonacchera M; Vitti P; Agretti P; Ceccarini G; Perri A; Cavaliere R; Mazzi B; Naccarato AG; Viacava P; Miccoli P; Pinchera A; Chiovato L
J Clin Endocrinol Metab; 1999 Nov; 84(11):4155-8. PubMed ID: 10566665
[TBL] [Abstract][Full Text] [Related]
34. Primary culture of cells from hyperfunctioning thyroid adenoma with an activating mutation of G alphas.
Kamiya Y; Murakami M; Yanagita Y; Koitabashi H; Nagamachi Y; Hosoi Y; Ogiwara T; Mizuma H; Iriuchijima T; Mori M
Mol Cell Endocrinol; 1998 Mar; 138(1-2):137-42. PubMed ID: 9685222
[TBL] [Abstract][Full Text] [Related]
35. RGS 2 expression is regulated by TSH and inhibits TSH receptor signaling.
Eszlinger M; Holzapfel HP; Voigt C; Arkenau C; Paschke R
Eur J Endocrinol; 2004 Sep; 151(3):383-90. PubMed ID: 15362969
[TBL] [Abstract][Full Text] [Related]
36. Detection of thyroid-stimulating hormone receptor and Gsalpha mutations: in 75 toxic thyroid nodules by denaturing gradient gel electrophoresis.
Trülzsch B; Krohn K; Wonerow P; Chey S; Holzapfel HP; Ackermann F; Führer D; Paschke R
J Mol Med (Berl); 2001; 78(12):684-91. PubMed ID: 11434721
[TBL] [Abstract][Full Text] [Related]
37. Somatic mutations in the VI transmembrane segment of the thyrotropin receptor constitutively activate cAMP signalling in thyroid hyperfunctioning adenomas.
Porcellini A; Ciullo I; Pannain S; Fenzi G; Avvedimento E
Oncogene; 1995 Sep; 11(6):1089-93. PubMed ID: 7566968
[TBL] [Abstract][Full Text] [Related]
38. Interactions between the extracellular domain and the extracellular loops as well as the 6th transmembrane domain are necessary for TSH receptor activation.
Neumann S; Claus M; Paschke R
Eur J Endocrinol; 2005 Apr; 152(4):625-34. PubMed ID: 15817920
[TBL] [Abstract][Full Text] [Related]
39. Expression of adenylyl cyclase types III and VI in human hyperfunctioning thyroid nodules.
Celano M; Arturi F; Presta I; Bruno R; Scarpelli D; Calvagno MG; Cristofaro C; Bulotta S; Giannasio P; Sacco R; Filetti S; Russo D
Mol Cell Endocrinol; 2003 May; 203(1-2):129-35. PubMed ID: 12782409
[TBL] [Abstract][Full Text] [Related]
40. Two novel mutations in the sixth transmembrane segment of the thyrotropin receptor gene causing hyperfunctioning thyroid nodules.
Gozu H; Avsar M; Bircan R; Claus M; Sahin S; Sezgin O; Deyneli O; Paschke R; Cirakoglu B; Akalin S
Thyroid; 2005 Apr; 15(4):389-97. PubMed ID: 15876166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
